Antiplatelet and oral anticoagulant therapies in chronic hemodialysis patients: prescribing practices and bleeding risk.

Date publication

août 2016

Journal

Pharmacoepidemiology and drug safety

Auteurs

Membres identifiés du Cancéropôle Est :
Pr THILLY Nathalie

Tous les auteurs :
Collette C, Clerc-Urmès I, Laborde-Castérot H, Frimat L, Ayav C, Peters N, Martin A, Agrinier N, Thilly N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27133538

Résumé

Results of previous studies assessing the risk of bleeding associated with prescription of antiplatelet (AP) and/or oral anticoagulant (AC) therapy to hemodialysis patients are conflicting. Our purpose was to describe practices for prescription of AP and AC in hemodialysis patients in the Lorraine region, and to assess their effect on the risk of major bleeding events.

Mots clés

Administration, Oral, Adult, Aged, Aged, 80 and over, Anticoagulants, administration & dosage, Cohort Studies, Drug Therapy, Combination, Female, Follow-Up Studies, Hemorrhage, chemically induced, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, administration & dosage, Probability, Proportional Hazards Models, Renal Dialysis, methods, Renal Insufficiency, Chronic, therapy, Retrospective Studies, Risk

Référence

Pharmacoepidemiol Drug Saf. 2016 Aug;25(8):935-43